Julie Reed Previews 2022: The Year of Expanded Access to Biosimilars

As the United States awaits market introduction for adalimumab biosimilars in 2023, 2022 is going to be the year of expanding access to biosimilars, according to Julie M. Reed, the new executive director of the Biosimilars Forum.

Transcript:

If 2020 was the year of the BPCIA [Biologics Price Competition and Innovation Act] rule change, and 2021 was the year of the first interchangeable biosimilar, and 2023 is going to be the year of adalimumab biosimilars, what milestone do you hope to see happen in 2022?

Access. We want to see the government deliver proactive incentive policies and increase access and uptake. We want to see payers improve their processes to include more biosimilars or all biosimilars on their formularies, not just one. We want to see BsUFA [Biosimilar User Fee Amendments of 2017], a robust FDA resourced biosimilars program, done. We want to see misinformation stopped before it goes out. We want to see HHS follow up on the president's executive order. We want to see the puzzle put together and the foundation that we need to capture all those savings. We want to lay all of that this year. It's time.